Dexa Scan denied as experimental or investigational by Medicare?

Medicare's specific coverage criteria for dexa scan are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Medicare Denies a DEXA Scan as Experimental

A DEXA (dual-energy X-ray absorptiometry) scan denial coded as "experimental" or "investigational" is unusual because DEXA is the standard-of-care modality for bone mineral density measurement and has held Medicare coverage for qualifying indications for decades. When this denial appears, it typically reflects one of the following: (1) the specific DEXA protocol or body site ordered falls outside Medicare's defined covered indications; (2) a non-standard application was coded in a way that triggered an investigational flag; or (3) a billing or modifier error caused the claim to route incorrectly. In any of these scenarios, the denial is contestable.

## Why This Denial Is Appealable

Medicare coverage is governed by National Coverage Determinations (NCDs) and Local Coverage Determinations (LCDs). If a covered indication applies to your patient, the experimental denial is a clear misclassification and should be overturned on Redetermination. If the application is genuinely non-standard, the appeal should demonstrate that the service is consistent with accepted standards of medical practice and that peer-reviewed support exists — even without citing specific trials.

## Federal Appeal Framework

• Medicare's five-level administrative appeal process applies: Redetermination → Qualified Independent Contractor Reconsideration → ALJ Hearing → Medicare Appeals Council → Federal Court.
• The Redetermination deadline is 120 days from the denial date; filing within 60 days is recommended.
• Expedited review is available when delay would jeopardize health or ability to regain maximum function.
• For Medicare Advantage plans, ACA §2719 external review rights also apply, adding an independent external reviewer step.

## Concrete Appeal Steps

1. Obtain the denial letter and identify the exact NCD or LCD cited as the basis for the experimental determination. 2. Go to cms.gov/medicare-coverage-database and pull the full text of that determination. 3. Map your patient's diagnosis codes, clinical presentation, and ordering rationale to the covered indications listed. 4. If the indication is covered, prepare a written argument that the denial is a misclassification and include a prescriber letter confirming the indication. 5. If the application is non-standard, gather clinical literature (without citing specific statistics) and professional society guidance supporting the use.

## Documentation Checklist

• Ordering provider's medical-necessity letter referencing the covered indication
• Relevant diagnosis codes and supporting clinical notes
• Printout of the applicable NCD/LCD with the covered indications highlighted
• Any professional society position statements supporting the ordered application (e.g., from the relevant specialty society)
• Prior imaging reports if relevant to demonstrating clinical context

## Criteria-Mapping Structure

Create a two-column table: left column lists each covered indication and requirement from the NCD/LCD; right column states the specific chart fact that satisfies it. If a requirement is not met, explain why the denial should nonetheless be reconsidered based on clinical necessity and accepted practice. Submit this mapping as the first page of your appeal letter.